Catalyst Event
Pfizer Inc (PFE) · Other
From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)
4/28/2026, 12:00:00 AM
Announced on April 28, 2026, Pfizer reached settlement agreements with generic drug manufacturers, extending the U.S. patent exclusivity for its blockbuster heart disease drug Vyndamax to June 1, 2031.
Korean Translation
2026년 4월 28일, 화이자가 제네릭 의약품 제조업체들과 합의에 도달하여 블록버스터 심장질환 치료제 빈다맥스(Vyndamax)의 미국 특허 독점권을 2031년 6월 1일까지 연장했다고 발표됨.
Related Recent Events
WuXi Biologics (Cayman) Inc (2269) · Other
The U.S. Office of Management and Budget (OMB) is scheduled to publish a full list of 'biotechnology companies of concern' (BCCs) by December 18, 2026, under the BIOSECURE Act; High importance is justified by the potential for severe regulatory risk causing a >10% price impact scheduled.
12/18/2026, 12:00:00 AM
WuXi AppTec Co Ltd (2359) · Other
Ex-dividend date on May 13, 2026, for the 2025 final cash dividend of RMB 1.57927 per share (RMB 15.7927 per 10 shares); low impact estimated as price typically adjusts by the dividend amount, scheduled.
5/13/2026, 12:00:00 AM
Gilead Sciences Inc (GILD) · Earnings Release
Q1 2026 earnings release is scheduled for 2026-05-07. This event is estimated to have a high price impact as quarterly results often drive significant market volatility scheduled.
5/7/2026, 12:00:00 AM
Kenvue Inc (KVUE) · Earnings Release
Kenvue will announce its first quarter 2026 financial results before the market opens on May 7, 2026. Based on historical earnings volatility, a 5% price impact is expected.
5/7/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer is scheduled to release its Q1 2026 earnings results before the market opens on May 5, 2026, scheduled.
5/5/2026, 12:00:00 AM
Vertex Pharmaceuticals Inc (VRTX) · Earnings Release
Vertex Pharmaceuticals is scheduled to announce its first-quarter 2026 financial results after the market closes on May 4, 2026. This earnings release is estimated to have a >=5% price impact, scheduled
5/4/2026, 12:00:00 AM